Molecular Partners (NASDAQ:MOLN) Trading Up 3.1% – Here’s What Happened

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN)’s stock price traded up 3.1% during mid-day trading on Monday . The stock traded as high as $4.43 and last traded at $4.36. 1,977 shares were traded during mid-day trading, a decline of 53% from the average session volume of 4,198 shares. The stock had previously closed at $4.23.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on MOLN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research note on Monday, December 22nd. JPMorgan Chase & Co. lowered their price target on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating on the stock in a research report on Monday, December 8th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Molecular Partners has an average rating of “Hold” and a consensus target price of $7.88.

Molecular Partners Trading Up 3.1%

The firm has a market capitalization of $176.06 million, a price-to-earnings ratio of -2.27 and a beta of 1.08. The firm has a fifty day moving average price of $4.14 and a 200 day moving average price of $3.87.

Molecular Partners (NASDAQ:MOLN) last issued its quarterly earnings data on Thursday, October 30th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.05. As a group, equities analysts predict that Molecular Partners AG Sponsored ADR will post -1.93 EPS for the current fiscal year.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.